Skip to main content
SpringerLink
Log in
Book cover

Seizures pp 333–356Cite as

Anticonvulsants in Acute Medical Illness

  • Chapter

  • 329 Accesses

Part of the book series: Current Clinical Neurology ((CCP))

Abstract

The choice of anticonvulsant agent for the medically ill patient with seizures will be influenced by a variety of factors. One important determinant will be the urgency with which seizure control is required. Both the severity of the patient’s illness and the risk of additional seizures will be important to this decision.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Physicians’ Desk Reference Montvale, NJ: Medical Economics, 2000.

    Google Scholar 

  2. Levy RH, Mattson RH, Meldrum BS (eds.), Antiepileptic Drugs. New York: Raven, 1995.

    Google Scholar 

  3. Wyllie E. The Treatment of Epilepsy: Principles and Practice. Baltimore, MD: Williams & Wilkins, 1997.

    Google Scholar 

  4. UCB Pharma. Keppra Prescribing Information. Smyrna, GA: UCB Pharma, 2000.

    Google Scholar 

  5. Novartis. Trileptal Prescribing Information. East Hanover, NJ: Novartis Pharmaceuticals, 2000.

    Google Scholar 

  6. Pharma E. Zonegran Prescribing Information. South San Francisco, CA: Elan Pharmaceuticals, 2000.

    Google Scholar 

  7. Donovan PJ, Cline D. Phenytoin administration by constant intravenous infusion: selective rates of administration. Ann Emerg Med 1991; 20: 139–142.

    Article  PubMed  CAS  Google Scholar 

  8. Meek PD, Davis SN, Collins DM, et al. Guidelines for nonemergency use of par-enteral phenytoin products: proceedings of an expert panel consensus process. Panel on Nonemergency Use of Parenteral Phenytoin Products. Arch Intern Med 1999; 159: 2639–2644.

    Article  PubMed  CAS  Google Scholar 

  9. Graves NM, Ramsay RE. Phenytoin and fosphenytoin. In: Wyllie E (ed.), The Treatment of Epilepsy. Baltimore, MD: Williams & Wilkins, 1997, pp 833–844.

    Google Scholar 

  10. Wilder BJ, Campbell K, Ramsay RE, et al. Safety and tolerance of multiple doses of intramuscular fosphenytoin substituted for oral phenytoin in epilepsy or neurosurgery. Arch Neurol 1996; 53: 764–768.

    Article  PubMed  CAS  Google Scholar 

  11. Jones AL, Proudfoot AT. Features and management of poisoning with modern drugs used to treat epilepsy. Q J Med 1998; 91: 325–332.

    Article  CAS  Google Scholar 

  12. Boesen F, Andersen EB, Jensen EK, Ladefoged SD. Cardiac conduction disturbances during carbamazepine therapy. Acta Neurol Scand 1983; 68: 49–52.

    PubMed  CAS  Google Scholar 

  13. Kasarskis EJ, Kuo CS, Berger R, Nelson KR. Carbamazepine-induced cardiac dysfunction. Characterization of two distinct clinical syndromes. Arch Internal Med 1992; 152: 186–191.

    Article  CAS  Google Scholar 

  14. Terrence CF, Fromm G. Congestive heart failure during carbamazepine therapy. Ann Neurol 1980; 8: 200–201.

    Article  PubMed  CAS  Google Scholar 

  15. Herzberg L. Carbamazepine and bradycardia. Lancet 1978; 1: 1097–1098.

    Article  PubMed  CAS  Google Scholar 

  16. Beerman B, Edhag O, Vallin H. Advanced heart block aggravated by carbamazepine. Br Heart J 1975; 37: 668–671.

    Article  Google Scholar 

  17. Sillanpaa M. Carbamazepine. In: Wyllie E (ed.), The Treatment of Epilepsy. Baltimore, MD: Williams & Wilkins, 1997, pp 808–823.

    Google Scholar 

  18. Sudhop T, Bauer J, Elger CE, von Bergmann K. Increased high-density lipoprotein cholesterol in patients with epilepsy treated with carbamazepine: a gender-related study. Epilepsia 1999; 40: 480–484.

    Article  PubMed  CAS  Google Scholar 

  19. Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989; 3: 70–76.

    Article  PubMed  CAS  Google Scholar 

  20. Bourgeois BFD. Phenobarbital and primidone. In: Wyllie E (ed.), The Treatment of Epilepsy. Baltimore, MD: Williams & Wilkins, 1997, pp 845–855.

    Google Scholar 

  21. Boggs J, Waterhouse E, DeLorenzo RJ. The use of antiepileptic medications in renal and liver disease. In: Wyllie E (ed.), The Treatment of Epilepsy. Baltimore, MD: Williams & Wilkins, 1997, pp 753–762.

    Google Scholar 

  22. Howard PA, Engen PL, Dunn MI. Phenytoin hypersensitivity syndrome: a case report. DICP 1991; 25: 929–932.

    PubMed  CAS  Google Scholar 

  23. Ratnaike RN, Schapel GJ, Purdie G, Rischbieth RH, Hoffmann S. Hyperammonaemia and hepatotoxicity during chronic valproate therapy: enhancement by combination with other antiepileptic drugs. Br J Clin Pharmacol 1986; 22: 100–103.

    PubMed  CAS  Google Scholar 

  24. Bryant AE III, Dreifuss FE. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology 1996; 46: 465–469.

    Article  PubMed  Google Scholar 

  25. Konig SA, Schenk M, Sick C, et al. Fatal liver failure associated with valproate therapy in a patient with Friedreich’s disease: review of valproate hepatotoxicity in adults. Epilepsia 1999; 40: 1036–1040.

    Article  PubMed  CAS  Google Scholar 

  26. Horowitz S, Patwardhan R, Marcus E. Hepatotoxic reactions associated with carbamazepine therapy. Epilepsia 1988; 29: 149–154.

    Article  PubMed  CAS  Google Scholar 

  27. Porto I, John EG, Heilliczer J. Removal of phenobarbital during continuous cycling peritoneal dialysis in a child. Pharmacotherapy 1997; 17: 832–835.

    PubMed  CAS  Google Scholar 

  28. Askmark H, Wiholm BE. Epidemiology of adverse reactions to carbamazepine as seen in a spontaneous reporting system. Acta Neurol Scand 1990; 81: 131–140.

    Article  PubMed  CAS  Google Scholar 

  29. Hogg RJ, Sawyer M, Hecox K, Eigenbrodt E. Carbamazepine-induced acute tubulointerstitial nephritis. J Pediatr 1981; 98: 830–832.

    Article  PubMed  CAS  Google Scholar 

  30. Dasgupta A, Jacques M, Malhotra D. Diminished protein binding capacity of uremic sera for valproate following hemodialysis: role of free fatty acids and uremic compounds. Am J Nephrol 1996; 16: 327–333.

    Article  PubMed  CAS  Google Scholar 

  31. Moreiras Plaza M, Rodriguez Goyanes G, Cuina L, Alonso R. On the toxicity of valproic-acid. Clin Nephrol 1999; 51: 187–189.

    PubMed  CAS  Google Scholar 

  32. Wong MO, Eldon MA, Keane WF, et al. Disposition of gabapentin in anuric subjects on hemodialysis. J Clin Pharmacol 1995; 35: 622–626.

    PubMed  CAS  Google Scholar 

  33. Gilmore RL. Seizures and antiepileptic drug use in transplant patients. Neurol Clin 1988; 6: 279–296.

    PubMed  CAS  Google Scholar 

  34. Sylvester RK, Lewis FB, Caldwell KC, Lobell M, Perri R, Sawchuk RA. Impaired phenytoin bioavailability secondary to cisplatinum, vinblastine, and bleomycin. Ther Drug Monit 1984; 6: 302–305.

    Article  PubMed  CAS  Google Scholar 

  35. Sobotka JL, Alexander B, Cook BL. A review of carbamazepine’s hematologic reactions and monitoring recommendations. DICP 1990; 24: 1214–1219.

    PubMed  CAS  Google Scholar 

  36. Holmes GL. Carbamazepine: toxicity. In: Levy RH, Mattson RH, Meldrum BS, (eds.), Antiepileptic Drugs. New York: Raven, 1995, pp 567–580.

    Google Scholar 

  37. Rapeport WG, Connell JC, Thompson GG, Moore MR, Brodie MJ. Effect of carbamazepine on haem biosynthesis in man. Eur J Clin Invest 1984; 14: 107–110.

    Article  PubMed  CAS  Google Scholar 

  38. Yeung Laiwah AA, Rapeport WG, Thompson GG, et al. Carbamazepine-induced non-hereditary acute porphyria. Lancet 1983; 1: 790–792.

    Article  PubMed  CAS  Google Scholar 

  39. Gidal B, Spencer N, Maly M, et al. Valproate-mediated disturbances of hemostasis: relationship to dose and plasma concentration. Neurology 1994; 44: 1418–1422.

    Article  PubMed  CAS  Google Scholar 

  40. Kis B, Szupera Z, Mezei Z, Gecse A, Telegdy G, Vecsei L. Valproate treatment and platelet function: the role of arachidonate metabolites. Epilepsia 1999; 40: 307–310.

    Article  PubMed  CAS  Google Scholar 

  41. MacDougall LG. Pure red cell aplasia associated with sodium valproate therapy. JAMA 1982; 247: 53–54.

    Article  PubMed  CAS  Google Scholar 

  42. Dreifuss FE. Valproic acid: toxicity. In: Levy RH, Mattson RH, Meldrum BS, (eds.), Antiepileptic Drugs. New York: Raven, 1995, pp 641–648.

    Google Scholar 

  43. Iivanainen M, Savolainen H. Side effects of phenobarbital and phenytoin during long-term treatment of epilepsy. Acta Neurol Scand Suppl 1983; 97: 49–67.

    Article  PubMed  CAS  Google Scholar 

  44. Bruni J. Phenytoin: toxicity. In: Levy RH, Mattson RH, Meldrum BS, (eds.), Antiepileptic Drugs. New York: Raven, 1995, pp 345–350.

    Google Scholar 

  45. Bardana EJ, Jr., Gabourel JD, Davies GH, Craig S. Effects of phenytoin on man’s immunity. Evaluation of changes in serum immunoglobulins, complement, and antinuclear antibody. Am J Med 1983; 74: 289–296.

    Article  PubMed  Google Scholar 

  46. Rosenthal CJ, Noguera CA, Coppola A, Kapelner SN. Pseudolymphoma with mycosis fungoides manifestations, hyperresponsiveness to diphenylhydantoin, and lymphocyte disregulation. Cancer 1982; 49: 2305–2314.

    Article  PubMed  CAS  Google Scholar 

  47. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985; 313: 145–151.

    Article  PubMed  CAS  Google Scholar 

  48. Baciewicz AM. Carbamazepine drug interactions. Ther Drug Monit 1986; 8: 305–317.

    Article  PubMed  CAS  Google Scholar 

  49. Kutt H. Phenobarbital: interactions with other drugs. In: Levy RH, Mattson RH, Meldrum BS (eds.), Antiepileptic Drugs. New York: Raven, 1995, pp 389–400.

    Google Scholar 

  50. Kutt H. Phenytoin: interactions with other drugs. Part 1: clinical aspects. In: Levy RH, Mattson RH, Meldrum BS (eds.), Antiepileptic Drugs. New York: Raven, 1995, pp 315–328.

    Google Scholar 

  51. Hess E. Drug-related lupus. N Engl J Med 1988; 318: 1460–1462.

    Article  PubMed  CAS  Google Scholar 

  52. Drory VE, Korczyn AD. Hypersensitivity vasculitis and systemic lupus erythematosis induced by anticonvulsants. Clin Neuropharmacol 1993; 16: 19–29.

    Article  PubMed  CAS  Google Scholar 

  53. Drory VE, Yust I, Korczyn AD. Carbamazepine-induced systemic lupus erythematosis. Clin Neuropharmacol 1989; 12: 115–118.

    Article  PubMed  CAS  Google Scholar 

  54. Kalif R, Houtkooper MA, Meyer JW, Goedhart DM, Augusteijn R, Meinardi H. Carbamazepine and serum sodium levels. Epilepsia 1984; 25: 390–397.

    Article  Google Scholar 

  55. Lahr MB. Hyponatremia during carbamazepine therapy. Clin Pharmacol Ther 1985; 37: 693–696.

    Article  PubMed  CAS  Google Scholar 

  56. Schachter SC, Vazquez B, Fisher RS, et al. Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology 1999; 52: 732–737.

    Article  PubMed  CAS  Google Scholar 

  57. Van Amelsvoort T, Bakshi R, Devaux CB, Schwabe S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia 1994; 35: 181–188.

    Article  PubMed  Google Scholar 

  58. Camfield PR, Bagnell P, Camfield CS, Tibbles JA. Pancreatitis due to valproic acid. Lancet 1979; 1: 1198–1199.

    Article  PubMed  CAS  Google Scholar 

  59. Williams LH, Reynolds RP, Emery JL. Pancreatitis during sodium valproate treatment. Arch Dis Child 1983; 58: 543–544.

    Article  PubMed  CAS  Google Scholar 

  60. Asconape JJ, Penry JK, Dreifuss FE, Riela A, Mirza W. Valproate-associated pan-creatitis. Epilepsia 1993; 34: 177–183.

    Article  PubMed  CAS  Google Scholar 

  61. Arafa M, Noble J, Royle SG, Trail IA, Allen J. Dupuytren’s and epilepsy revisited. J Hand Surg 1992; 17: 221–224.

    CAS  Google Scholar 

  62. Critchley EM, Vakil SD, Hayward HW, Owen VM. Dupuytren’s disease in epilepsy: result of prolonged administration of anticonvulsants. J Neurol Neurosurg Psychiatry 1976; 39: 498–503.

    Article  PubMed  CAS  Google Scholar 

  63. Dansky LV, Andermann E, Rosenblatt D, Sherwin AL, Andermann E Anticonvulsants, folate levels, and pregnancy outcome: a prospective study. Ann Neurol 1987; 21: 176–182.

    CAS  Google Scholar 

  64. Dansky LV, Rosenblatt DS, Andermann E. Mechanisms of teratogenesis: folic acid and antiepileptic therapy. Neurology 1992; 42: 32–42.

    Article  PubMed  CAS  Google Scholar 

  65. Morrell MJ. Guidelines for the care of women with epilepsy. Neurology 1998; 51: S21 - S27.

    Article  PubMed  CAS  Google Scholar 

  66. Lewis DP, Van Dyke DC, Stumbo PJ, Berg MJ. Drug and environmental factors associated with adverse pregnancy outcomes. Part I: Antiepileptic drugs, contraceptives, smoking, and folate. Ann Pharmacother 1998; 32: 802–817.

    Article  PubMed  CAS  Google Scholar 

  67. Nulman I, Laslo D, Koren G. Treatment of epilepsy in pregnancy. Drugs 1999; 57: 535–544.

    Article  PubMed  CAS  Google Scholar 

  68. Gelineau-van Waes J, Bennett GD, Finnell RH. Phenytoin-induced alterations in craniofacial gene expression. Teratology 1999; 59: 23–34.

    Article  PubMed  CAS  Google Scholar 

  69. DiLiberti JH, Farndon PA, Dennis NR, Curry CJ. The fetal valproate syndrome. Am J Med Genet 1984; 19: 473–481.

    Article  PubMed  CAS  Google Scholar 

  70. Jones KL, Lacro RV, Johnson KA, Adams J. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 1989; 320: 1661–1666.

    Article  PubMed  CAS  Google Scholar 

  71. Seip M. Growth retardation, dysmorphic facies, and minor malformations following massive exposure to phenobarbitone in utero. Acta Paediat Scand 1976; 65: 617–621.

    Article  PubMed  CAS  Google Scholar 

  72. Malone FD, D’Alton ME. Drugs in pregnancy: anticonvulsants. Semin Perinatol 1997; 21: 114–123.

    Article  PubMed  CAS  Google Scholar 

  73. American Academy of Pediatrics Committee on Drugs: The transfer of drugs and other chemicals into human milk. Pediatrics 1994; 93: 137–150.

    Google Scholar 

  74. Bauer LA. Interference of oral phenytoin absorption by continuous nasogastric feedings. Neurology 1982; 32: 570–572.

    Article  PubMed  CAS  Google Scholar 

  75. Doak KK, Haas CE, Dunnigan KJ, et al. Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings. Pharmacotherapy 1998; 18: 637–645.

    PubMed  CAS  Google Scholar 

  76. Bialer M, Cloyd JC. Drug formulations and routes of administration. In: Levy RH (ed.), Antiepileptic Drugs. New York: Raven, 1995, pp 161–178.

    Google Scholar 

  77. Van Hoogdalem EJ, De Boer AG, Briemer DD. Pharmacokinetics of rectal drug administration, part 1. Clin Pharmacokinet 1991; 21: 11–26.

    Article  PubMed  Google Scholar 

  78. Kuile F, Nosten F, Chongsuphajaisiddhi T, Holloway P, Maelankirri L, White NJ. Absorption of intramuscular phenobarbitone in children with severe falciparum malaria. Eur J Clin Pharmacol 1992; 42: 107–110.

    Article  PubMed  CAS  Google Scholar 

  79. Graves NM, Holmes GB, Kriel RL, Jones-Saete C, Ong B, Ehresman DJ. Relative bioavailability of rectally administered phenobarbital sodium parenteral solution. DICP 1989; 23: 565–568.

    PubMed  CAS  Google Scholar 

  80. Jones-Saete C, Kriel RL, Cloyd JC. External leakage from feeding gastrostomies in patients receiving valproate sprinkle. Epilepsia 1992; 33: 692–695.

    Article  PubMed  CAS  Google Scholar 

  81. Margarit MV, Rodriguez IC, Cerezo A. Rectal bioavailability of water-soluble drugs: sodium valproate. J Pharm Pharmacol 1991; 43: 721–725.

    Article  PubMed  CAS  Google Scholar 

  82. Holmes GB, Rosenfeld WE, Graves NM, Remmel RP, Carlson GH, Kriel RD. Absorption of valproic acid suppositories in human volunteers. Arch Neurol 1989; 46: 906–909.

    Article  PubMed  CAS  Google Scholar 

  83. Gallo BV, Slater JD, Toledo C, DeToledo J, Ramsay RE. Pharmacokinetics and muscle histopathology of intramuscular valproate. Epilepsy Res 1997; 28: 11–15.

    Article  PubMed  CAS  Google Scholar 

  84. Graves NM, Kriel RL, Jones-Saete C, Cloyd JC. Relative bioavailability of rectally administered carbamazepine suspension in humans. Epilepsia 1985; 26: 429–433.

    Article  PubMed  CAS  Google Scholar 

  85. Olson WL. Carbamazepine suppository. Neurology 1990; 40: 1472–1473.

    Article  PubMed  CAS  Google Scholar 

  86. Nagatomi A, Mishima M, Tsuzuki O, Ohdo S, Higuchi S. Utility of a rectal suppository containing the antiepileptic drug zonisamide. Biol Pharm Bull 1997; 20: 892–896.

    Article  PubMed  CAS  Google Scholar 

  87. Dreifuss FE, Rosman NP, Cloyd JC, et al. A comparison of rectal diazepam gel and placebo for acute repetitive seizures. N Engl J Med 1998; 338: 1869–1875.

    Article  PubMed  CAS  Google Scholar 

  88. Gram-Hansen P, Schultz A. Plasma concentrations following oral and sublingual administration of lorazepam. Int J Clin Pharmacol Ther Toxicol 1988; 26: 323–324.

    PubMed  CAS  Google Scholar 

  89. Rey E, Treluyer JM, Pons G. Pharmacokinetic optimization of benzodiazepine therapy for acute seizures. Focus on delivery routes. Clin Pharmacokinet 1999; 36: 409–424.

    Article  PubMed  CAS  Google Scholar 

  90. Scheepers M, Scheepers B, Clough P. Midazolam via the intranasal route: an effective rescue medication for severe epilepsy in adults with learning disability. Seizure 1998; 7: 509–512.

    Article  PubMed  CAS  Google Scholar 

  91. Scott RC, Besag FM, Boyd SG, Berry D, Neville BG. Buccal absorption of midazolam: pharmacokinetics and EEG pharmacodynamics Epilepsia 1998; 39: 290–294.

    Article  PubMed  CAS  Google Scholar 

  92. Scott RC, Besag FM, Neville BG. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet 1999; 353: 623–626.

    Article  PubMed  CAS  Google Scholar 

  93. Fischer JH. Drug Interactions with Antiepileptic Drugs. New York: McMahon Publishing Group, 1999.

    Google Scholar 

  94. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin Pharmacokinet 1996; 31: 198–214.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Colin Roberts MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jacqueline A. French MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Clinical Neurological Sciences, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland

    Norman Delanty MB, FRCPI (Consultant Neurologist) (Consultant Neurologist)

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media New York

About this chapter

Cite this chapter

Roberts, C., French, J.A. (2002). Anticonvulsants in Acute Medical Illness. In: Delanty, N. (eds) Seizures. Current Clinical Neurology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-094-0_21

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-094-0_21

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-207-0

  • Online ISBN: 978-1-59259-094-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation